

Second announcement and call for posters

# Fibrosis

1<sup>st</sup> RSC / SCI symposium on Fibrosis Disease:  
medicinal chemistry progress from biological  
target to the clinic

Tuesday, 10<sup>th</sup> November 2015

UCB, Slough, UK



Inspired by patients.  
Driven by science.

Organised by  
RSC's Biological and Medicinal Chemistry Sector, and  
SCI's Fine Chemicals Group

## Synopsis

Fibrosis disease is the result of a dysregulated wound healing process and is responsible for considerable patient mortality affecting multiple organs in diseases such as idiopathic pulmonary fibrosis (IPF), diabetic nephropathy, steatohepatitis and systemic sclerosis. Fibrosis disease pathology is often complex and this inaugural symposium on fibrosis will provide mechanistic insight and progress in medicinal chemistry and drug discovery from experts across the world.

## Programme

- 09.30 *Welcome and opening remarks* - Luis Castro, UCB
- 09.35 **Keynote:** *The common denominator of chronic disease - Fibrosis* - Robert M Strieter, Novartis
- 10.20 *Out of the frying-pan PI3K and into....? Generation of a robust pathway toolbox to investigate the anti-fibrotic behaviour of GSK2126458A* - Simon Peace, GlaxoSmithKline
- 10.50 Refreshments
- 11.20 *Design of mechanism-based amine oxidase inhibitors for the treatment of fibrosis* - Jonathan Foot, Pharmaxis
- 11.50 *Tissue transglutaminase - a credible therapeutic target in the treatment of fibrotic disease due to its multifunctional roles?* - Martin Griffin, Aston University
- 12.20 Flash presentations - Autotaxin, University of Strathclyde
- 12.30 Lunch
- 13.30 *Structure activity relationships of av integrin antagonists - industrial medicinal chemistry with 4th year MSci undergraduates* - Simon Macdonald, GlaxoSmithKline, and Thomas McNally, University of Nottingham
- 14.00 *Harnessing our understanding of scleroderma to develop and validate innovative anti-fibrotic therapies* - David Abraham, University College London
- 14.30 *Discovery and quantitation of novel liver fibrosis biomarkers: towards the first antibody-free biomarker assay for liver fibrosis* - Bevin Gangadharan, University of Oxford
- 14.40 Refreshments
- 15.10 *Role of NOX enzymes in fibrotic diseases: development of a 1st in class NOX1/4 inhibitor GKT137831* - Ursula Ney, Genkyotex
- 15.40 *Does CB2 agonism protect from inflammation related organ damage and fibrosis?* - Uwe Grether, F Hoffmann-La Roche
- 16.10 to be confirmed - late breaker
- 16.50 *Closing remarks* - Luis Castro, UCB

## Call for Posters

Posters are invited for display throughout the meeting. Please download a template from the website, and send a one-page abstract to the secretariat.

## Registration Fees and Bursaries

- £120 RSC or SCI member
- £150 Non-member
- £60 RSC or SCI student\* member
- £75 Student\* non-member
- £30 Late fee - for payment received from 8th October onwards
- £500 Exhibition stand space with either two trade stand staff\*\* or one full delegate
- £119 One night's B&B accommodation at the Copthorne Slough Windsor

\* Student is undergraduate or post-graduate, not post-doc. Some student bursaries are available.

\*\* Trade stand staff have no access to technical sessions.

## Sponsors

Contact the Secretariat for details of sponsorship opportunities. We are grateful to our confirmed sponsors.



Inspired by patients.  
Driven by science.

## Organising Committee

Richard Hatley (co-chairman),  
GlaxoSmithKline

Mark Healy, Novartis

Fabien Lecomte, UCB Pharma

Simon Peace (co-chairman),  
GlaxoSmithKline

Mihiro Sunose, Sygnature Discovery

## Contact Secretariat

Maggi Churchouse, 3 East Barn, Market Weston Road, Thelneyham, Diss IP22 1JJ, UK  
telephone and fax +44 (0)1359 221004, [maggi@maggichurchouseevents.co.uk](mailto:maggi@maggichurchouseevents.co.uk)

**Websites:** [www.maggichurchouseevents.co.uk/bmcs](http://www.maggichurchouseevents.co.uk/bmcs)

[www.rsc.org/bmcs](http://www.rsc.org/bmcs)

[www.soci.org/events](http://www.soci.org/events)